Polymeric nanoparticles for drug delivery

MA Beach, U Nayanathara, Y Gao, C Zhang… - Chemical …, 2024 - ACS Publications
The recent emergence of nanomedicine has revolutionized the therapeutic landscape and
necessitated the creation of more sophisticated drug delivery systems. Polymeric …

Mucosal vaccines: Strategies and challenges

M Li, Y Wang, Y Sun, H Cui, SJ Zhu, HJ Qiu - Immunology letters, 2020 - Elsevier
Mucosal immunization has potential benefits over conventional parenteral immunization,
eliciting immune defense in both mucosal and systemic tissue for protecting from pathogen …

Vaccines, adjuvants and key factors for mucosal immune response

VA Correa, AI Portilho, E De Gaspari - Immunology, 2022 - Wiley Online Library
Vaccines are the most effective tool to control infectious diseases, which provoke significant
morbidity and mortality rates. Most vaccines are administered through the parenteral route …

The role of mucoadhesion and mucopenetration in the immune response induced by polymer-based mucosal adjuvants

N Vasquez-Martínez, D Guillen, SA Moreno-Mendieta… - Polymers, 2023 - mdpi.com
Mucus is a viscoelastic gel that acts as a protective barrier for epithelial surfaces. The
mucosal vehicles and adjuvants need to pass through the mucus layer to make drugs and …

Bioavailability by design—Vitamin D3 liposomal delivery vehicles

P Dałek, D Drabik, H Wołczańska, A Foryś… - … , Biology and Medicine, 2022 - Elsevier
Vitamin D3 deficiency has serious health consequences, as demonstrated by its effect on
severity and recovery after COVID-19 infection. Because of high hydrophobicity, its …

Mucosal vaccine delivery using mucoadhesive polymer particulate systems

CS Cho, SK Hwang, MJ Gu, CG Kim, SK Kim… - Tissue engineering and …, 2021 - Springer
Vaccination has been recently attracted as one of the most successful medical treatments of
the prevalence of many infectious diseases. Mucosal vaccination has been interested in …

Pulmonary delivery of mucosal nanovaccines

W Tang, Y Zhang, G Zhu - Nanoscale, 2022 - pubs.rsc.org
Mucosal vaccination can elicit both systemic and mucosal immunity, and therefore has the
potential to not only treat mucosal immune diseases, prevent the pathogen infection at the …

The role of mucosal immunity and recombinant probiotics in SARS-CoV2 vaccine development

S Moradi-Kalbolandi, K Majidzadeh-A… - Probiotics and …, 2021 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), causing the 2019 novel
coronavirus disease (COVID-19), was introduced by WHO (World Health Organization) as …

[HTML][HTML] Technological approaches for improving vaccination compliance and coverage

C Lemoine, A Thakur, D Krajišnik, R Guyon, S Longet… - Vaccines, 2020 - mdpi.com
Vaccination has been well recognised as a critically important tool in preventing infectious
disease, yet incomplete immunisation coverage remains a major obstacle to achieving …

The development of a human Brucella mucosal vaccine: What should be considered?

T Tian, Y Zhu, J Shi, K Shang, Z Yin, H Shi, Y He… - Life Sciences, 2024 - Elsevier
Brucellosis is a chronic infectious disease that is zoonotic in nature. Brucella can infect
humans through interactions with livestock, primarily via the digestive tract, respiratory tract …